Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Daraxonrasib + Ivonescimab + RMC-6291
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Daraxonrasib RMC 6236|RMC6236|RMC-6236 RAS Inhibitor (Pan) 14 Daraxonrasib (RMC-6236) forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348).
Ivonescimab AK112|AK 112|AK-112|SMT112|SMT 112|SMT-112 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 VEGFA Antibody 5 Ivonescimab is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in antitumor activity (PMID: 37593227).
RMC-6291 RMC6291RM032|RM-032|RMC 6291 KRAS G12C inhibitor 36 RMC-6291 is a small molecule that selectively inhibits active KRAS G12C by forming a tri-complex with KRAS G12C and cyclophilin A, potentially resulting in decreased RAS signaling and tumor cell proliferation, and reduced tumor growth (PMID: 37590355).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT07397338 Phase Ib/II Ivonescimab + RMC-9805 Cetuximab + Ivonescimab + RMC-9805 Ivonescimab + RMC-6291 Daraxonrasib + Ivonescimab + RMC-6291 Carboplatin + Ivonescimab + Pemetrexed Disodium + RMC-6291 Cisplatin + Ivonescimab + Pemetrexed Disodium + RMC-6291 Daraxonrasib + Ivonescimab Carboplatin + Daraxonrasib + Ivonescimab + Pemetrexed Disodium Cisplatin + Daraxonrasib + Ivonescimab + Pemetrexed Disodium Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Recruiting USA 0


Additional content available in Icon for CKB-BoostCKB BOOST